|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2250 GBX | -.--% |
|
+2.27% | - |
| 03-01 | Kanabo Group PLC Announces Termination Of Director Appointment of Sharon Malka, Effective February 27, 2026 | CI |
| 12-12 | Quantum Helium increases Sagebrush project interest | AN |
| Market Cap | 5.38M 7.24M 6.26M 5.84M 10.14M 688M 10.26M 68.64M 26.85M 344M 27.16M 26.59M 1.14B | P/E 2022 |
-1.15x | P/E 2023 | -1.88x |
|---|---|---|---|---|---|
| Enterprise Value | 2.44M 3.28M 2.84M 2.65M 4.6M 312M 4.65M 31.13M 12.18M 156M 12.32M 12.06M 518M | EV / Sales 2022 |
8.33x | EV / Sales 2023 | 16.5x |
| Free-Float |
93.73% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 week | +2.27% | ||
| Current month | +2.27% | ||
| 1 month | +2.27% |
| Current year | 0.22 |  | 0.22 |
| 1 year | 0.22 | | 0.22 |
| 3 years | 0.15 | | 3.2 |
| 5 years | 0.15 | | 26 |
| 10 years | 0.15 | | 51 |
| Manager | Title | Age | Since |
|---|---|---|---|
Avihu Tamir
CEO | Chief Executive Officer | - | - |
Assaf Vardimon
DFI | Director of Finance/CFO | 48 | - |
Suleman Sacranie
CTO | Chief Tech/Sci/R&D Officer | 37 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Avihu Tamir
BRD | Director/Board Member | - | - |
Sharon Malka
BRD | Director/Board Member | 53 | 2023-05-03 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 10/31/24 | Others | Chairman | 18,011,111 | 2.8479% | ||
| 10/29/24 | Free | Chairman | 17,361,111 | 2.7452% | ||
| 8/28/24 | Buy | Chief Technology Officer | 75,187 | 0.0119% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +2.27% | -.--% | -88.46% | 1.87M | |
| +4.86% | -4.16% | +52.13% | +160.26% | 995B | |
| +1.04% | -3.43% | +50.60% | +52.38% | 614B | |
| +0.98% | -6.46% | +24.85% | +66.66% | 431B | |
| +1.96% | -0.87% | +43.02% | +37.60% | 353B | |
| -0.11% | -4.56% | +31.59% | +39.73% | 293B | |
| +2.52% | -6.99% | +8.08% | +10.32% | 245B | |
| +4.57% | +3.75% | +35.07% | +67.64% | 210B | |
| -4.32% | -12.25% | -5.97% | -44.56% | 210B | |
| -2.58% | -1.91% | +15.06% | +67.46% | 168B | |
| Average | +0.79% | -5.52% | +25.44% | +36.90% | 351.82B | |
| Weighted average by Cap. | +0.71% | -5.89% | +36.58% | +75.03% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 603K 812K 703K 655K 1.14M 77.22M 1.15M 7.7M 3.01M 38.62M 3.05M 2.98M 128M | 895K 1.21M 1.04M 973K 1.69M 115M 1.71M 11.43M 4.47M 57.33M 4.52M 4.43M 190M |
| Net income | -6.87M -9.25M -8M -7.46M -12.95M -879M -13.1M -87.69M -34.3M -440M -34.7M -33.96M -1.46B | -7.99M -10.75M -9.31M -8.68M -15.07M -1.02B -15.24M -102M -39.9M -512M -40.35M -39.5M -1.7B |
| Net Debt | -3.01M -4.06M -3.51M -3.27M -5.68M -386M -5.75M -38.46M -15.05M -193M -15.22M -14.9M -640M | -2.94M -3.96M -3.42M -3.19M -5.54M -376M -5.61M -37.52M -14.68M -188M -14.84M -14.53M -624M |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- KNB Stock
Select your edition
All financial news and data tailored to specific country editions
